STOCK TITAN

Perspective Therapeutics (CATX) Financials

CATX NYSE
Trailing 12 months to September 30, 2026
Net Income -$122.9M n/m YoY
EPS (Diluted) -$1.25 YoY not available
Free Cash Flow -$138.8M n/m YoY
Operating Cash Flow -$108.1M n/m YoY
Market Cap $91.0M as of Nov 20, 2026
Price / Sales n/m no full year of revenue reported yet
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book 0.3x on $294.7M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 9, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CATX SEC filings page.

This page shows Perspective Therapeutics, Inc. (CATX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CATX FY2025

The numbers depict a development-stage business where research investment is expanding, operating cash use is rising, and debt remains limited.

R&D rose 102.3% to $84.2M in FY2025. Operating cash flow moved from -$18.3M in FY2024 to -$82.5M in FY2025, linking the investment ramp to heavier cash use.

FY2025 free cash flow was -$95.2M versus operating cash flow of -$82.5M, so capital spending added to operating cash consumption. By contrast, FY2024 free cash flow of -$72.7M was far below operating cash flow of -$18.3M, making that year's cash pressure more capital-intensive.

FY2025 liabilities were 22.5% of assets, while long-term debt was $1.6M; this is an equity-funded balance sheet, not a debt-funded one. The reported liquidity comparison equaled 21.1 months of FY2025 operating outflow, describing balance-sheet coverage rather than profitability.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Financial health score not available

We do not publish a peer-relative financial health score for Perspective Therapeutics, Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.

Piotroski F-Score Partial
1/7

Perspective Therapeutics, Inc. passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality No Cash Backing
N/A

Perspective Therapeutics, Inc. reported a net loss of $103.1M while operations used $82.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA
-$33.1M
YoYn/m
QoQn/m

Perspective Therapeutics, Inc.'s EBITDA was -$33.1M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income
-$32.4M
YoYn/m
QoQn/m

Perspective Therapeutics, Inc. reported a net loss of $32.4M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$0.27
QoQn/m

Perspective Therapeutics, Inc. earned -$0.27 per diluted share (EPS) in Q3 2026. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Revenue

Not reported for Q3 2026.

Cash & Balance Sheet

Free Cash Flow
-$35.9M
YoYn/m
QoQn/m
5Y CAGRn/m
10Y CAGRn/m

Perspective Therapeutics, Inc. recorded an outflow of $35.9M in free cash flow in Q3 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Debt
$41.0M
YoY+53.4%
QoQ-15.4%
5Y CAGR-7.8%
10Y CAGR+17.1%

Perspective Therapeutics, Inc. held $41.0M in cash against $1.6M in long-term debt as of Q3 2026.

Shares Outstanding
121M
QoQ+5.8%

Perspective Therapeutics, Inc. had 121M shares outstanding in Q3 2026. Against the prior quarter it is up 5.8%.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Return on Equity
-11.0%
YoY-0.3pp
QoQ-2.7pp

Perspective Therapeutics, Inc.'s quarterly ROE was -11.0% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 0.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 2.7 percentage points.

Gross Margin

Not reported for Q3 2026.

Operating Margin

Not reported for Q3 2026.

Net Margin

Not reported for Q3 2026.

Capital Allocation

R&D Spending
$26.1M
YoY+28.2%
QoQ+21.0%

Perspective Therapeutics, Inc. invested $26.1M in research and development in Q3 2026. This represents an increase of 28.2% from the same quarter a year earlier. Against the prior quarter it is up 21.0%.

Capital Expenditures
$4.5M
YoY+127.7%
QoQ-68.1%
5Y CAGR+142.6%
10Y CAGR+40.9%

Perspective Therapeutics, Inc. invested $4.5M in capex in Q3 2026, funding long-term assets and infrastructure. This represents an increase of 127.7% from the same quarter a year earlier. Against the prior quarter it is down 68.1%.

Share Buybacks

Not reported for Q3 2026.

CATX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CATX quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
R&D Expenses$26.1M+28.2%$21.5M+29.6%$21.4M+49.1%$32.9M+155.6%$20.3M+69.1%$16.6M+79.2%$14.3M+92.3%$12.9M
SG&A Expenses$8.3M+7.0%$7.8M+1.1%$7.0M-10.9%$7.0M-15.7%$7.7M+10.8%$7.7M+39.8%$7.8M+33.4%$8.2M
Operating Income-$34.3Mn/m-$29.3Mn/m-$28.3Mn/m-$39.8Mn/m-$27.9Mn/m-$24.0Mn/m-$21.8Mn/m-$45.0M
EBITDA-$33.1Mn/m-$28.1Mn/m-$27.2Mn/m-$38.8Mn/m-$27.1Mn/m-$23.3Mn/m-$21.1Mn/m-$44.3M
Net Income-$32.4Mn/m-$26.8Mn/m-$26.2Mn/m-$37.5Mn/m-$26.0Mn/m-$21.5Mn/m-$18.2Mn/m-$40.2M
EPS (Basic)-$0.27-$0.22-$0.25n/m-$0.51n/m-$0.35n/m-$0.29n/m-$0.25n/m-$0.61n/m
EPS (Diluted)-$0.27-$0.22-$0.25n/m-$0.51n/m-$0.35n/m-$0.29n/m-$0.25n/m-$0.61n/m
Diluted Shares (Avg)121M121M104M+43.2%N/A74M+5.2%74M+11.4%72M+46.1%N/A

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense, Income Tax.

CATX Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CATX quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'25FilingQ4'2410-K
Total Assets$365.7M+24.0%$392.0M+26.2%$410.8M+24.7%$267.0M-21.7%$294.8M-24.6%$310.7M-19.5%$329.3M+18.3%$341.1M+248.4%
Current Assets$205.3M+15.0%$241.5M+23.3%$275.4M+27.6%$148.4M-35.8%$178.5M-33.9%$196.0M-33.4%$215.7M+14.6%$231.2M+1272.9%
Cash & Equivalents$41.0M+53.4%$48.5M+68.1%$54.0M+21.5%$30.6M-50.3%$26.8M-88.2%$28.8M-88.6%$44.4M-68.8%$61.6M+566.6%
Short-Term Investments$160.7M+9.0%$188.4M+15.8%$217.0M+29.7%$114.1M-31.0%$147.4M+255.9%$162.7M+298.2%$167.3M+334.2%$165.3Mn/m
Accounts Receivable$13K-92.7%$269K+19.6%$58K-25.6%$6K-94.8%$179K-17.5%$225K+58.5%$78K-92.2%$116K-90.0%
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
GoodwillN/AN/AN/AN/AN/AN/AN/A$0-100.0%
Total Liabilities$71.0M+35.0%$68.2M+51.4%$63.3M+41.7%$59.9M+18.9%$52.6M-16.1%$45.0M+0.2%$44.7M-7.6%$50.4M+122.1%
Current Liabilities$39.6M+92.1%$36.5M+181.4%$31.5M+148.3%$28.7M+57.3%$20.6M-26.7%$13.0M+22.4%$12.7M-12.6%$18.2M+16.4%
Non-Current Liabilities$31.4M-1.8%$31.6M-1.3%$31.8M-0.6%$31.3M-2.9%$32.0M-7.4%$32.0M-6.6%$32.0M-5.5%$32.2M+356.9%
Long-Term Debt$1.6M-3.4%$1.6M-3.3%$1.6M-3.2%$1.6M-3.1%$1.6M-3.0%$1.7M-3.2%$1.7M-2.9%$1.7M-2.8%
Total Equity$294.7M+21.7%$323.9M+21.9%$347.4M+22.1%$207.0M-28.8%$242.2M-26.3%$265.7M-22.1%$284.6M+23.8%$290.7M+286.6%
Retained Earnings-$420.3Mn/m-$387.8Mn/m-$361.0Mn/m-$334.8Mn/m-$297.4Mn/m-$271.4Mn/m-$249.9Mn/m-$231.7Mn/m

Not reported in any period shown, so not listed: Inventory.

CATX Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CATX quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow-$31.4Mn/m-$20.6Mn/m-$31.5Mn/m-$24.7Mn/m-$16.3M-584.0%-$20.0Mn/m-$21.6M-255.8%-$26.6Mn/m
Depreciation & Amortization$1.2M+53.9%$1.1M+55.7%$1.1M+53.8%$1.0M+42.6%$775K+15.8%$733K+28.1%$732K+105.6%$709K
Stock-Based Compensation$3.1M+45.0%$3.0M+26.8%$2.6M+21.7%N/A$2.2M+10.5%$2.4M+309.4%$2.1M+219.8%N/A
Capital Expenditures$4.5M+127.7%$14.2M+1283.5%$6.9M+47.3%$5.1M-65.3%$2.0M-93.3%$1.0M+1.1%$4.7M-48.7%$14.6M+16320.2%
Free Cash Flow-$35.9Mn/m-$34.8Mn/m-$38.3Mn/m-$29.7Mn/m-$18.3Mn/m-$21.0Mn/m-$26.2M-649.4%-$41.2Mn/m
Investing Cash Flow$23.7M+69.6%$15.0M+252.2%-$109.6Mn/m$28.5Mn/m$14.0Mn/m$4.3Mn/m-$5.6Mn/m-$138.6Mn/m
Financing Cash Flow$175K-17.8%$147K+11.4%$164.4M+1548.1%-$13K-103.8%$213K-66.1%$132K-99.9%$10.0M-94.0%$345K-2.0%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

CATX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CATX quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Return on Equity-11.0%-0.3pp-8.3%-0.2pp-7.5%-1.1pp-18.1%-4.3pp-10.7%-6.1pp-8.1%-4.7pp-6.4%-1.0pp-13.8%
Return on Assets-8.9%-0.1pp-6.8%+0.1pp-6.4%-0.9pp-14.0%-2.3pp-8.8%-4.9pp-6.9%-3.9pp-5.5%-1.1pp-11.8%
Current Ratio5.18-3.5x6.61-8.5x8.75-8.3x5.17-7.5x8.66-0.9x15.09-12.6x17.02+4.0x12.68+11.6x
Debt-to-Equity0.010.0x0.000.0x0.000.0x0.010.0x0.010.0x0.010.0x0.010.0x0.010.0x
Liabilities-to-Equity0.240.0x0.210.0x0.180.0x0.29+0.1x0.220.0x0.170.0x0.16-0.1x0.17-0.1x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Perspective Therapeutics, Inc. CATX FY2025 N/A -$103.1M N/A $91.0M —
Quanterix Corporation QTRX FY2025 $138.9M -$107.2M -77.1% $93.1M 43/100
Apyx Medical Corporation APYX FY2025 $52.8M -$11.2M -21.2% $101.1M 46/100
Nyxoah SA NYXH FY2025 $11.8M -$105.7M N/A $82.0M 56/100
Owlet, Inc. OWLT FY2025 $105.7M -$39.7M -37.5% $87.6M 55/100
Pulmonx Corporation LUNG FY2025 $90.5M -$54.0M -59.7% $111.9M 57/100

Frequently Asked Questions

No, Perspective Therapeutics, Inc. (CATX) reported a net loss of $122.9M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $103.1M.

Perspective Therapeutics, Inc. (CATX) reported diluted earnings per share of -$1.40 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Perspective Therapeutics, Inc. (CATX) had EBITDA of -$110.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

As of fiscal year 2025, Perspective Therapeutics, Inc. (CATX) had $30.6M in cash and equivalents against $1.6M in long-term debt.

Perspective Therapeutics, Inc. (CATX) has a return on equity of -49.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Perspective Therapeutics, Inc. (CATX) recorded an outflow of $95.2M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Perspective Therapeutics, Inc. (CATX) recorded an outflow of $82.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Perspective Therapeutics, Inc. (CATX) had $267.0M in total assets as of fiscal year 2025, including both current and long-term assets.

Perspective Therapeutics, Inc. (CATX) invested $12.7M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Perspective Therapeutics, Inc. (CATX) invested $84.2M in research and development during fiscal year 2025.

Perspective Therapeutics, Inc. (CATX) had 114M shares outstanding as of fiscal year 2025.

Perspective Therapeutics, Inc. (CATX) had a current ratio of 5.17 as of fiscal year 2025, which is generally considered healthy.

Perspective Therapeutics, Inc. (CATX) had a debt-to-equity ratio of 0.01 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.

Perspective Therapeutics, Inc. (CATX) had a liabilities-to-equity ratio of 0.29 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.

Perspective Therapeutics, Inc. (CATX) had a return on assets of -38.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Perspective Therapeutics, Inc. (CATX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $91.0M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Perspective Therapeutics, Inc. (CATX) has no price-to-sales ratio at the moment: no full year of revenue reported yet. The market capitalization is $91.0M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, Perspective Therapeutics, Inc. (CATX) held $144.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $82.5M over that year. Dividing the one by the other, the reported balance equals about 21 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Perspective Therapeutics, Inc. (CATX) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Perspective Therapeutics, Inc. (CATX) reported a net loss of $103.1M while operations used $82.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Back to top